RAG Classification List *Please Note This List Does Not Include Exhaustive Information About Formulation

Total Page:16

File Type:pdf, Size:1020Kb

RAG Classification List *Please Note This List Does Not Include Exhaustive Information About Formulation RAG Classification List *please note this list does not include exhaustive information about formulation. Please check formulary website for full details Name of Drug/Classification Status Comments Abatacept Red Abciximab Red Abiraterone Red Abraxane (Paclitaxel – albumin bound Red formulation) Acamprosate Green Plus Acarbose Green For existing patients only. Unless on for Plus reactive hypoglycaemia on advice of specialist Acetazolamide injection Red Injection: 500 mg vial Acetylcysteine Green Eye drops: acetylcysteine 5%, hypromellose Plus 0.35% (Ilube®) Aciclovir injection (for IV infusion) Red Adalimumab Red Adenosine Red Afatinib Red Aflibercept Red Intravitreal injection: 4 mg/ 0.1mL (dose 2mg/0.05ml) Agomelatine Green Plus Ajmaline injection Red Diagnostic agent Alemtuzumab Red Alfentanil Green Injection: 500 micrograms/1 mL, 5 mg/1 mL Plus Alfentanil Red Injection (amps): 1 mg/2 mL, 5 mg /1 mL Alimemazine Red Hospital use only as paediatric pre- Tablets:10mg medication Syrup: 7.5mg/5ml, 30mg/5ml Alirocumab Red Aliskiren Tablets Green Plus Alpha tocopheryl acetate Green Suspension: 500 mg/5 mL Plus Capsules: 200units (for use in children with cystic fibrosis) Alpha tocopheryl acetate Red Injection: 100mg/2ml (unlicensed) Alprostadil Green Plus Alteplase Red Amantadine Green plus Amikacin Injection Red Aminophylline Injection Red Amiodarone Infusion Red Amiodarone Tablets Amber Sunderland Joint Formulary Committee RAG List V1.22 26.918 Page 1 of 22 Amisulpride Green Plus Amoxicillin Injection Red Amphotericin Red Amsacrine Red Anagrelide Red Capsules: 500 micrograms (2nd line for ITP and patients at risk of essential thrombocythaemia) Anakinra Red Anastrozole Green Plus Antacid with oxetacaine Green Unlicensed Plus Antithymocyte Immunoglobulin (Rabbit) Red Antithymocyte Immunoglobulin (Horse) Red Apomorphine Amber Apraclonidine Red Eye drops: 0.5% Unit dose eye drops: 1% Apremilast Red Aprepitant Red Capsules Aptivus Red Oral solution/capsules (tipranavir) Argatroban Red Aripiprazole (tablets and long acting Green injection) Plus Arsenic Trioxide Red Artesunate Red Aspirin dispersible tablets Red For pre-term labor Aspirin suppositories Green 300mg for use in patients following stroke Plus Atezolizumab Red Atracurium besilate (besylate) Red Atomoxetine Amber Atosiban Red Atripla Red Tablets (efavirenz/emtricitabine/tenofovir) Atropine sulphate Red Avelumab Red Axitinib Red Azacitidine Red Azathioprine Amber Azithromycin Green For COPD indication Plus Aztreonam Red Baricitinib Red BCG Connaught Red Belimumab Red Bendamustine Red Benzathine penicillin Red Benzbromarone Red Unlicensed Benzylpenicillin Red Eye drops: 100,000 units/mL Betamethasone Red For pre-term labor Betamethasone Solution Green Scalp application - As ear drops for eczema Sunderland Joint Formulary Committee RAG List V1.22 26.918 Page 2 of 22 Plus Betamethasone tablets Green Used as mouth gargle Plus Bevacizumab Red Avastin is available as a treatment option for wet AMD in situations where ophthalmologists feel, in discussion with their patients, that the licensed options are unsuitable Bicalutamide Green Plus Biosimilar infliximab (Inflectra) Red Bivalirudin Red Bismuth and lodoform paste Red Bleomycin Red Blinatumomab Red Boceprevir Red Boric acid Red Bortezomib Red Bosentan Red Bosutinib Red Botulinum toxin type A Red Brentuximab Red Brivaracetam Green Plus Brodalumab RED Bromocriptine Green Plus Bupivacaine hydrochloride Red Buprenorphine Sublingual Tablets Green Sublingual Tablets: 400 micrograms, 2 mg, Plus 8 mg Buprenorphine Sublingual Tablets Red Sublingual Tablets: 200micrograms for the treatment of post-operative pain Buserelin Green Plus Buspirone Green Plus Busulfan (Busulphan) Red C1-esterase inhibitor Injection (Berinert®) Red Cabazitaxel Red Cabergoline Green Plus Calcitriol Green Capsules: 0.25 micrograms, 0.5 micrograms Plus Calcium chloride Red Injection:10% equivalent to calcium 6.8 mmol/10 mL Calcium Folinate (Folinic Acid) Red Calcium gluconate Red Injection: 10%, equivalent to calcium 2.25 mmol/10 mL Calcium/Magnesium salts Green Tablets: Calcium acetate 435 mg and Plus Magnesium carbonate 235 mg (Osvaren) Canagliflozin Green Sunderland Joint Formulary Committee RAG List V1.22 26.918 Page 3 of 22 Plus Capecitabine Red Carbamazepine Green Plus Carbon Dioxide (CO2) Red Carboplatin Red Carboprost Red Carfilzomib Red Carmustine Red Caspofungin Red Cefixime Green Plus Ceftazidime Red Ceftolozane and tazobactam (Zerbaxa) Red Cefuroxime Red Celsentri Red Tablets (maraviroc) Ceritinib Red Certolizumab pegol Red Cetuximab Red Chloral Hydrate Red For use in paediatrics only Elixir: 143.3mg/5ml Chlorambucil Red Chloramphenicol Injection Red Chlorhexidine eye drops Red Chorionic gonadotrophin (Ovitrelle, Red Pregnyl) Chorionic gonadotrophin alfa Red Ciclosporin eye drops Green Eye drops: 0.1% Plus Ciclosporin eye drops Red P/F unit dose eye drops: 0.05% Ciclosporin (oral) Amber Ciclosporin (Sandimmun®) Red IV Infusion: 50mg in 1ml & 250mg in 5ml concentrate (oily) Cinacalcet Amber For the treatment of primary hyperparathyrodism Cinacalcet Red For the treatment of secondary hyperparahyrodism Ciprofloxacin IV infusion Red Ciprofloxacin eye drops Red Cisplatin Red Cladribine (Leustat®) Red Clarithromycin Injection Red Clindamycin Injection Red Clobazam Green Plus Clomifene Green Plus Clomiphene Red For ovulation inducation Clonazepam Green Plus Sunderland Joint Formulary Committee RAG List V1.22 26.918 Page 4 of 22 Clonidine Hydrochloride Ampoules Red Clonidine Hydrochloride Suspension Red Clonidine Hydrochloride Tablets Green Plus Clopidogrel Green Plus Clozapine Tablets Red Co-amoxiclav Injection Red Cocaine Red Cocaine Red P/F eye drops: 4% Co-careldopa with entacapone Green Plus Colesevelam Green Plus Codeine Phosphate Injection Red Colecalciferol Green For bariatric indications Plus (Note: green for non-bariatric indications) Colistimethate sodium Red Collagenase Red Xiapex Combivir Red Tablets (lamivudine/zidovudine) Co-trimoxazole IV infusion Red Crixivan Red Indinavir Crizotinib Red Cyclopentolate hydrochloride with Red Eye drops (preservative free): 1% phenylephrine: Cyclophosphamide Red Cyproterone Acetate 50mg & 100mg Green Indication: Gender Dysphoria, Hirsutism Tablets Plus Cytarabine Red Dabrafenib Red Daclatasvir Red Dacarbazine Red Dactinomycin Red Danaparoid sodium Red Dantrolene Green Capsules: 25 mg, 100 mg Plus Dantrolene sodium Red Injection (vials): 20 mg Dapagliflozin Green Plus Dapsone Amber Daptomycin Green Plus Daratumumab Red Darbepoetin alfa Amber Prefilled syringes: 10, 15, 20,30, 40, 50, 60, 80, 100, 150, 300 micrograms Sureclick pens: 20,40,60,80, 100, 300micrograms Daunorubicin Red Deferasirox Red Degarelix (Firmagon) Green Plus Sunderland Joint Formulary Committee RAG List V1.22 26.918 Page 5 of 22 Demeclocycline Red Denosumab Amber JFC recommended status changed from Amber to Green Plus at May 2018 meeting. Green Plus leaflet reviewed at June MOGG meeting but was deferred to August meeting as required changes. Status changed and leaflet published in error on 11.7.18. Error noted on 16.7.18, Status reverted to amber and Green Plus leaflet removed and replaced with Amber leaflet 16.7.18. Consultants have been informed of this. Descovey Red Tablets (emtricitabine/rilpivirine/tenofovir) note various strengths – see formulary for details Desferrioxamine mesilate Red Desflurane Red Desmopressin injection Red Desmopressin metered nasal spray Red 150mcg Desmopressin oral lyophilisates Green Noqdirna Plus Desmopressin Green Metered nasal spray: 10 micrograms/spray plus Tablets: 100 micrograms, 200 micrograms Oral lyophilisate: 60 micrograms, 120 micrograms, 240 micrograms and Intranasal solution 100micrograms/1ml Dexamethasone injection Red Dexamethasone Red Intravitreal implant: Dexamfetamine Amber Dexamfetamine Red For use in narcolepsy for doses > 30mg Dexamfetamine Green For use in narcolepsy for doses < 30mg Plus Dexmedetomidine Red Dexrazoxane Red Diaminopyridine Red Diamorphine injection Green Plus Diazoxide Green Plus Diclofenac injection Red Diclofenac sodium Red Eye drops/Unit dose eye drops (preservative-free): 0.1% Diethylstilbestrol (Stilboestrol) Green Plus Dihydrocodeine modified release Green Plus Dimethyl Fumarate Red Dinoprostone Red Sunderland Joint Formulary Committee RAG List V1.22 26.918 Page 6 of 22 Dipyridamole Green Plus Disodium Edetate Red Disodium pamidronate Red Disopyramide Capsules Green Plus Disopyramide Injection Red Dobutamine Injection Red Docetaxel Red Donepezil Green Plus Dopamine hydrochloride Red Dopexamine Red Dornase alfa Red Doxapram Red Doxapram hydrochloride Red Doxorubicin Red Doxycycline Injection Red Dronedarone Amber Dulaglutide Green Plus Duloxetine Green For moderate to severe stress incontinence Plus in combination with supervised pelvic floor excercises Eculizumab Red Edrophonium chloride Red Hospital use only Edurant Red Tablets (rilpivirine) Eflornithine cream Green Vaniqa Plus Eltrombopag Red Eluxadoline Green Plus Empagliflozin Green Plus Emtriva Red Capsules and oral solution (emtricabine) Entacapone Green Plus Entecavir Red Entonox (N2O 50% : O2 50%) Red Enzalutamide Red Ephedrine Red Epirubicin Red Epivir Red Tablets and oral solution (lamivudine) Eplerenone Green Epoetin alfa (Eprex) Amber Epoetin Beta (NeoRecormon) Amber Epoetin Zeta Amber Sunderland Joint Formulary Committee RAG List V1.22 26.918 Page 7 of 22 Epoprostenol Red Ergocalciferol Red Injection: 300,000 units/1 mL, 600,000 units/2 mL Ergometrine Red Erlotinib Red Ethambutol 400mg in 5ml unlicensed
Recommended publications
  • Use of Chemical Chelators As Reversal Agents for Drug
    (19) TZZ_ _ZZZ_T (11) EP 1 210 090 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 31/724 (2006.01) A61K 31/194 (2006.01) 18.06.2014 Bulletin 2014/25 A61P 39/04 (2006.01) (21) Application number: 00964006.1 (86) International application number: PCT/EP2000/007694 (22) Date of filing: 07.08.2000 (87) International publication number: WO 2001/012202 (22.02.2001 Gazette 2001/08) (54) USE OF CHEMICAL CHELATORS AS REVERSAL AGENTS FOR DRUG- INDUCED NEUROMUSCULAR BLOCK VERWENDUNG VON CHEMISCHEN CHELATOREN ZUR UMKEHRUNG VON PHARMAKOLOGISCH-INDUZIERTER NEUROMUSKULÄRER BLOCKIERUNG UTILISATION D’AGENTS CHIMIQUES CHELATANTS COMME AGENTS DE NEUTRALISATION DU BLOCAGE NEUROMUSCULAIRE PROVOQUE PAR DES MEDICAMENTS (84) Designated Contracting States: (56) References cited: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU AU-A- 3 662 895 MC NL PT SE • B DESIRE: "Inactivaton of sarin and soman by (30) Priority: 13.08.1999 EP 99306411 cyclodextrins in vitro" EXPERIENTIA, vol. 43, no. 4, 1987, pages 395-397, XP000907287 (43) Date of publication of application: • B. DESIRE: "Interaction of soman with beta- 05.06.2002 Bulletin 2002/23 cyclodextrin" FUNDAMENTAL AND APPLIED TOXICOLOGY, vol. 7, no. 4, 1986, pages 647-657, (73) Proprietor: Merck Sharp & Dohme B.V. XP000911170 2031 BN Haarlem (NL) • C. MAY: "Development of a toxin-binding agent as a treatment for tunicamycinuracil toxicity: (72) Inventors: protection against tunicamycin poisoning of • BOM, Antonius, Helena, Adolf sheep" AUSTRALIAN VETERINARY JOURNAL, Ratho, Midlothian EH28 8NY (GB) vol. 76, no.
    [Show full text]
  • Download Document
    FAM001159-0001 intervals of 4-7 days to usual dose of 75-100 mg Dolmatil® (Sanofi-Synthelabo) ~ 100 rag/5 mL, thioridazine 100 rag/ per course and max. 4 injections; max. duration of daily according to response; CHILD not recom- Tablets, both scored, sulpiride 200 rag, net price ’ net price 300 mL = £7.14. Label: 2 treatment 2 weeks---if maintenance treatment mended 100-tabpack=£13.85;400mg(f/c), 100-tab ! fNote. These suspensions should not be diluted but the necessary change to an oral antipsychotic 2-3 Short-term adjunctive management of severe pack = £36¯29. Label: 2 .: :~t~a preparations may be mixed with each other to days after last injection, or to a longer acting anti- anxiety, 15-20rag daily in divided doses; max. Sulpltil® (Pharmacia) I~ ~0iovid¢ intermediate strengths psychotic depot injection given concomitantly 40 mg daily; CHILD not recommended Tablets, scored, sulpiride 200 rag. Net price 28-tab "ff~-~p, brown, thioridazine (as hydrochloride) with last injection of zuclopenthixol acetate; By deep intramuscular injection, psychoses, mania, pack = £4.29; 112-tab pack = £12.85. Label: 2 ~ff.~5"~mg/5 mL, net price 300 mL = £1.98. Label: 2 CHILD not recommended prochlorperazine mesilate 12.5-25 mg 2-3 times Sulpor® (Rosemont) IPoMI Clopi~ol Acuphase® (Lundbeck) daily; CHILD not recommended Oral solution, sugar-free, lemon- and aniseed-fla. LUOPERAZINE Injection (oily), zuclopenthixol acetate 50 mg/mL. By rectum in suppositories, psychoses, mania, the voured, sulpiride 200 mg/5 mL, net price 150 mL (’~’n~ications: see under Dose; anti-emetic (section Net price I-mL amp = £5.20; 2-mL amp = £10.03 equivalent of prochlorperazine maleate 25 mg 2- = £27.00.
    [Show full text]
  • PMBJP Product.Pdf
    Sr. Drug Generic Name of the Medicine Unit Size MRP Therapeutic Category No. Code Analgesic & Antipyretic / Muscle 1 1 Aceclofenac 100mg and Paracetamol 325 mg Tablet 10's 10's 8.00 relaxants Analgesic & Antipyretic / Muscle 2 2 Aceclofenac Tablets IP 100mg 10's 10's 4.37 relaxants Acetaminophen 325 + Tramadol Hydrochloride 37.5 film Analgesic & Antipyretic / Muscle 3 4 10's 8.00 coated Tablet 10's relaxants Analgesic & Antipyretic / Muscle 4 5 ASPIRIN Tablets IP 150 mg 14's 14's 2.70 relaxants DICLOFENAC 50 mg+ PARACETAMOL 325 mg+ Analgesic & Antipyretic / Muscle 5 6 10's 11.30 CHLORZOXAZONE 500 mg Tablets 10's relaxants Diclofenac Sodium 50mg + Serratiopeptidase 10mg Tablet Analgesic & Antipyretic / Muscle 6 8 10's 12.00 10's relaxants Analgesic & Antipyretic / Muscle 7 9 Diclofenac Sodium (SR) 100 mg Tablet 10's 10's 6.12 relaxants Analgesic & Antipyretic / Muscle 8 10 Diclofenac Sodium 25mg per ml Inj. IP 3 ml 3 ml 2.00 relaxants Analgesic & Antipyretic / Muscle 9 11 Diclofenac Sodium 50 mg Tablet 10's 10's 2.90 relaxants Analgesic & Antipyretic / Muscle 10 12 Etoricoxilb Tablets IP 120mg 10's 10's 33.00 relaxants Analgesic & Antipyretic / Muscle 11 13 Etoricoxilb Tablets IP 90mg 10's 10's 25.00 relaxants Analgesic & Antipyretic / Muscle 12 14 Ibuprofen 400 mg + Paracetamol 325 mg Tablet 10's 15's 5.50 relaxants Analgesic & Antipyretic / Muscle 13 15 Ibuprofen 200 mg film coated Tablet 10's 10's 1.80 relaxants Analgesic & Antipyretic / Muscle 14 16 Ibuprofen 400 mg film coated Tablet 10's 15's 3.50 relaxants Analgesic & Antipyretic
    [Show full text]
  • 10 Mg/Ml Solution for Injection/Infusion Atracurium
    Package leaflet: Information for the patient <Product name> 10 mg/ml solution for injection/infusion Atracurium besilate Read all of this leaflet carefully before you start using this medicine because it contains important information for you. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or nurse. - If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet 1. What <Product name> is and what it is used for 2. What you need to know before you receive <Product name> 3. How to use <Product name> 4. Possible side effects 5. How to store <Product name> 6. Contents of the pack and other information 1. What <Product name> is and what it is used for <Product name> belongs to a group of medicines called muscle relaxants. <Product name> is used during surgery to relax muscles and to assist with inserting a breathing tube and with artificial breathing. It is also used to help with artificial breathing at patients in intensive care units. 2. What you need to know before you receive <Product name> <Product name> cannot be administered: - if you are allergic to atracurium besilate, cisatracurium or any of the other ingredients of this medicine (listed in section 6). If you think that this applies to you talk to your doctor before <Product name> is administered to you. Warnings and precautions Talk to your doctor or nurse before using <Product name>: - if you have an allergy or bronchial
    [Show full text]
  • Prohibited Substances List
    Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR). Neither the List nor the EADCM Regulations are in current usage. Both come into effect on 1 January 2010. The current list of FEI prohibited substances remains in effect until 31 December 2009 and can be found at Annex II Vet Regs (11th edition) Changes in this List : Shaded row means that either removed or allowed at certain limits only SUBSTANCE ACTIVITY Banned Substances 1 Acebutolol Beta blocker 2 Acefylline Bronchodilator 3 Acemetacin NSAID 4 Acenocoumarol Anticoagulant 5 Acetanilid Analgesic/anti-pyretic 6 Acetohexamide Pancreatic stimulant 7 Acetominophen (Paracetamol) Analgesic/anti-pyretic 8 Acetophenazine Antipsychotic 9 Acetylmorphine Narcotic 10 Adinazolam Anxiolytic 11 Adiphenine Anti-spasmodic 12 Adrafinil Stimulant 13 Adrenaline Stimulant 14 Adrenochrome Haemostatic 15 Alclofenac NSAID 16 Alcuronium Muscle relaxant 17 Aldosterone Hormone 18 Alfentanil Narcotic 19 Allopurinol Xanthine oxidase inhibitor (anti-hyperuricaemia) 20 Almotriptan 5 HT agonist (anti-migraine) 21 Alphadolone acetate Neurosteriod 22 Alphaprodine Opiod analgesic 23 Alpidem Anxiolytic 24 Alprazolam Anxiolytic 25 Alprenolol Beta blocker 26 Althesin IV anaesthetic 27 Althiazide Diuretic 28 Altrenogest (in males and gelidngs) Oestrus suppression 29 Alverine Antispasmodic 30 Amantadine Dopaminergic 31 Ambenonium Cholinesterase inhibition 32 Ambucetamide Antispasmodic 33 Amethocaine Local anaesthetic 34 Amfepramone Stimulant 35 Amfetaminil Stimulant 36 Amidephrine Vasoconstrictor 37 Amiloride Diuretic 1 Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR).
    [Show full text]
  • (Mibg) Scintigraphy: Procedure Guidelines for Tumour Imaging
    Eur J Nucl Med Mol Imaging (2010) 37:2436–2446 DOI 10.1007/s00259-010-1545-7 GUIDELINES 131I/123I-Metaiodobenzylguanidine (mIBG) scintigraphy: procedure guidelines for tumour imaging Emilio Bombardieri & Francesco Giammarile & Cumali Aktolun & Richard P. Baum & Angelika Bischof Delaloye & Lorenzo Maffioli & Roy Moncayo & Luc Mortelmans & Giovanna Pepe & Sven N. Reske & Maria R. Castellani & Arturo Chiti Published online: 20 July 2010 # EANM 2010 Abstract The aim of this document is to provide general existing procedures for neuroendocrine tumours. The information about mIBG scintigraphy in cancer patients. guidelines should therefore not be taken as exclusive of The guidelines describe the mIBG scintigraphy protocol other nuclear medicine modalities that can be used to obtain currently used in clinical routine, but do not include all comparable results. It is important to remember that the The European Association has written and approved guidelines to promote the use of nuclear medicine procedures with high quality. These general recommendations cannot be applied to all patients in all practice settings. The guidelines should not be deemed inclusive of all proper procedures and exclusive of other procedures reasonably directed to obtaining the same results. The spectrum of patients seen in a specialized practice setting may be different than the spectrum usually seen in a more general setting. The appropriateness of a procedure will depend in part on the prevalence of disease in the patient population. In addition, resources available for patient care may vary greatly from one European country or one medical facility to another. For these reasons, guidelines cannot be rigidly applied. These guidelines summarize the views of the Oncology Committee of the EANM and reflect recommendations for which the EANM cannot be held responsible.
    [Show full text]
  • (12) United States Patent (10) Patent N0.: US 7,265,099 B1 Born Et A1
    US007265099B1 (12) United States Patent (10) Patent N0.: US 7,265,099 B1 Born et a1. (45) Date of Patent: *Sep. 4, 2007 (54) USE OF CHEMICAL CHELATORS AS Tarver, G. et al “2-O-Substituted cyclodextrins as reversal REVERSAL AGENTS FOR DRUG-INDUCED agents . ” Bioorg. Med. Chem. (2002) vol. 10, pp 1819-1827.* NEUROMUSCULAR BLOCK Zhang, M. “Drug-speci?c cyclodextrins . ” Drugs of the Future (2003) vol. 28, no 4, pp 347-354.* (75) Inventors: Antonius Helena Adolf Bom, Lee, C. “Structure, conformation, and action of neuromuscular Midlothian (GB); Alan William Muir, blocking drugs” Brit. J. Anesth. (2001) vol. 87, no 5, pp 755-769.* Lanark (GB); David Rees, Gothenburg B Desire: “Inactivation of sarin and soman by cyclodextrins in (SE) vitro” EXPERIENTIA, vol. 43, No. 4, 1987, pp. 395-397. B. Desire: “Interaction of soman with beta-cyclodextrin” Funda (73) Assignee: Organon N.V., Oss (NL) mental and Applied Toxicology, vol. 7, No. 4, 1986, pp. 647-657. ( * ) Notice: Subject to any disclaimer, the term of this C. May: “Development of a toxin-bindng agent as a treatment for patent is extended or adjusted under 35 tunicamycinuracil toxicity: protection against tunicamycin poison U.S.C. 154(b) by 0 days. ing of sheep” Australian Veterinary Journal, vol. 76, No. 11, 1998 pp. 752-756. This patent is subject to a terminal dis K. Uekama: “Effects of cyclodextrins on chlorpromaZine-induced claimer. haemolysis and nervous systems responses” J. Pharm. Pharmacol., vol. 33, No. 11, 1981, pp. 707-710. (21) Appl. No.: 10/049,393 T. Irie: “Protective mechanism of beta-cyclodextrin for the hemolysis induced With phenothiazine neuroleptics in vitro” J.
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • EANM Procedure Guidelines for 131I-Meta-Iodobenzylguanidine (131I-Mibg) Therapy
    Eur J Nucl Med Mol Imaging (2008) 35:1039–1047 DOI 10.1007/s00259-008-0715-3 GUIDELINES EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy Francesco Giammarile & Arturo Chiti & Michael Lassmann & Boudewijn Brans & Glenn Flux Published online: 15 February 2008 # EANM 2008 Abstract Meta-iodobenzylguanidine, or Iobenguane, is an nervous system. The neuroendocrine system is derived from a aralkylguanidine resulting from the combination of the family of cells originating in the neural crest, characterized by benzyl group of bretylium and the guanidine group of an ability to incorporate amine precursors with subsequent guanethidine (an adrenergic neurone blocker). It is a decarboxylation. The purpose of this guideline is to assist noradrenaline (norepinephrine) analogue and so-called nuclear medicine practitioners to evaluate patients who might “false” neurotransmitter. This radiopharmaceutical, labeled be candidates for 131I-meta-iodobenzylguanidine to treat with 131I, could be used as a radiotherapeutic metabolic agent neuro-ectodermal tumours, to provide information for in neuroectodermal tumours, that are derived from the performing this treatment and to understand and evaluate primitive neural crest which develops to form the sympathetic the consequences of therapy. F. Giammarile (*) Keywords Guidelines . Therapy . mIBG CH Lyon Sud, EA 3738, HCL, UCBL, 165 Chemin du Grand Revoyet, Purpose 69495 Pierre Benite Cedex, France e-mail: [email protected] The purpose of this guideline is to assist nuclear medicine A. Chiti practitioners to U.O. di Medicina Nucleare, Istituto Clinico Humanitas, via Manzoni, 56, 1. Evaluate patients who might be candidates for 131I-meta- 20089 Rozzano (MI), Italy iodobenzylguanidine (mIBG) to treat neuro-ectodermal e-mail: [email protected] tumours M.
    [Show full text]
  • New Zealand Data Sheet
    NEW ZEALAND DATA SHEET 1. TRACRIUM (atracurium besilate 10 mg/mL injections (2.5 mL and 5.0 mL)) 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each 2.5 mL ampoule contains 25 mg atracurium besilate, each 5 mL ampoule contains 50 mg atracurium besilate. TRACRIUM 2.5 mL and 5.0 mL injections contain no preservative. 3. PHARMACEUTICAL FORM TRACRIUM injection is a clear, faintly yellow, sterile, aqueous solution in a glass ampoule containing 10 mg/mL atracurium besilate. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications TRACRIUM is a highly selective, competitive or non-depolarising neuromuscular blocking agent which is used as an adjunct to general anaesthesia to enable tracheal intubation to be performed and to relax skeletal muscles during surgery or controlled ventilation, and to facilitate mechanical ventilation in Intensive Care Unit (ICU) patients. 4.2 Dose and method of administration Use in adults Injection TRACRIUM is administered by intravenous injection. The dosage range for adults is 0.3 to 0.6 mg/kg (depending on the duration of full block required) and will provide adequate relaxation for 15 to 35 minutes. Endotracheal intubation can usually be accomplished within 90 seconds from the intravenous injection of 0.5 to 0.6 mg/kg. Full block can be prolonged with supplementary doses of 0.1 to 0.2 mg/kg as required. Successive supplementary dosing does not give rise to accumulation of neuromuscular blocking effect. Spontaneous recovery from the end of full block occurs in about 35 minutes as measured by the restoration of the tetanic response to 95% of normal neuromuscular function.
    [Show full text]
  • Handbook of Drugs in Intensive Care: an A
    This page intentionally left blank This page intentionally left blank Handbook of Drugs in Intensive Care Fourth edition This book is dedicated to Georgina Paw Handbook of Drugs in Intensive Care An A-Z Guide Fourth edition Henry G W Paw BPharm MRPharmS MBBS FRCA Consultant in Anaesthesia and Intensive Care York Hospital York Rob Shulman BSc (Pharm) MRPharmS Dip Clin Pham, DHC (Pharm) Lead Pharmacist in Critical Care University College London Hospitals London CAMBRIDGE UNIVERSITY PRESS Cambridge, New York, Melbourne, Madrid, Cape Town, Singapore, São Paulo, Delhi, Dubai, Tokyo Cambridge University Press The Edinburgh Building, Cambridge CB2 8RU, UK Published in the United States of America by Cambridge University Press, New York www.cambridge.org Information on this title: www.cambridge.org/9780521757157 © H. Paw and R. Shulman 2010 This publication is in copyright. Subject to statutory exception and to the provision of relevant collective licensing agreements, no reproduction of any part may take place without the written permission of Cambridge University Press. First published in print format 2010 ISBN-13 978-0-521-75715-7 Paperback Cambridge University Press has no responsibility for the persistence or accuracy of urls for external or third-party internet websites referred to in this publication, and does not guarantee that any content on such websites is, or will remain, accurate or appropriate. CONTENTS Introduction vii How to use this book viii Abbreviations x Acknowledgements xiii DRUGS: An A–Z Guide 1 SHORT NOTES 229 Routes of
    [Show full text]
  • Prodrugs of Morpholine Tachykinin Receptor
    Europäisches Patentamt *EP000748320B1* (19) European Patent Office Office européen des brevets (11) EP 0 748 320 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.7: C07D 413/06, C07D 265/32, of the grant of the patent: C07F 9/6558, A61K 31/535 13.11.2002 Bulletin 2002/46 (86) International application number: (21) Application number: 95912667.3 PCT/US95/02551 (22) Date of filing: 28.02.1995 (87) International publication number: WO 95/023798 (08.09.1995 Gazette 1995/38) (54) PRODRUGS OF MORPHOLINE TACHYKININ RECEPTOR ANTAGONISTS MORPHOLINWIRKSTOFFVORLÄUFER ALS TACHYKININRECEPTORANTAGONISTEN PROMEDICAMENTS A BASE D’ANTAGONISTES DE RECEPTEURS DE LA MORPHOLINE TACHYKININE (84) Designated Contracting States: • MacCOSS, Malcolm AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT Rahway, NJ 07065 (US) SE • MILLS, Sander, G. Designated Extension States: Rahway, NJ 07065 (US) LT SI (74) Representative: Hiscock, Ian James et al (30) Priority: 04.03.1994 US 206771 European Patent Department, Merck & Co., Inc., (43) Date of publication of application: Terlings Park, 18.12.1996 Bulletin 1996/51 Eastwick Road Harlow, Essex CM20 2QR (GB) (73) Proprietor: Merck & Co., Inc. Rahway New Jersey 07065-0900 (US) (56) References cited: EP-A- 0 528 495 EP-A- 0 577 394 (72) Inventors: • DORN, Conrad, P. Remarks: Rahway, NJ 07065 (US) The file contains technical information submitted • HALE, Jeffrey, J. after the application was filed and not included in this Rahway, NJ 07065 (US) specification Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted.
    [Show full text]